European Association of Urology Guidelines on Sexual and Reproductive Health-2021 Update: Male Sexual Dysfunction.

Ejaculatory disorders Erectile dysfunction Guidelines Haemospermia Hypogonadism Male Premature ejaculation Sexual dysfunction Testosterone

Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
09 2021
Historique:
received: 10 04 2021
accepted: 09 06 2021
pubmed: 30 6 2021
medline: 15 3 2022
entrez: 29 6 2021
Statut: ppublish

Résumé

The present summary of the European Association of Urology (EAU) guidelines is based on the latest guidelines on male sexual health published in March 2021, with a last comprehensive update in January 2021. To present a summary of the 2021 version of the EAU guidelines on sexual and reproductive health. A literature review was performed up to January 2021. The guidelines were updated, and a strength rating for each recommendation was included based on either a systematic review of the evidence or a consensus opinion from the expert panel. Late-onset hypogonadism is a clinical condition in the ageing male combining low levels of circulating testosterone and specific symptoms associated with impaired hormone production and/or action. A comprehensive diagnostic and therapeutic work-up, along with screening recommendations and contraindications, is provided. Erectile dysfunction (ED) is the persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance. Along with a detailed basic and advanced diagnostic approach, a novel decision-making algorithm for treating ED in order to better tailor therapy to individual patients is provided. The EAU guidelines have adopted the definition of premature ejaculation (PE), which has been developed by the International Society for Sexual Medicine. After the subtype of PE has been defined, patient's expectations should be discussed thoroughly and pharmacotherapy must be considered as the first-line treatment for patients with lifelong PE, whereas treating the underlying cause must be the initial goal for patients with acquired PE. Haemospermia is defined as the appearance of blood in the ejaculate. Several reasons of haemospermia have been acknowledged; the primary goal over the management work-up is to exclude malignant conditions and treat any other underlying cause. The 2021 guidelines on sexual and reproductive health summarise the most recent findings, and advise in terms of diagnosis and treatment of male hypogonadism and sexual dysfunction for their use in clinical practice. These guidelines reflect the multidisciplinary nature of their management. Updated European Association of Urology guidelines on sexual and reproductive health are presented, addressing the diagnosis and treatment of the most prevalent conditions in men. Patients must be fully informed of all relevant diagnostic and therapeutic options and, together with their treating physicians, decide on optimal personalised management strategies.

Identifiants

pubmed: 34183196
pii: S0302-2838(21)01813-3
doi: 10.1016/j.eururo.2021.06.007
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

333-357

Informations de copyright

Copyright © 2021 European Association of Urology. All rights reserved.

Auteurs

Andrea Salonia (A)

Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; University Vita-Salute San Raffaele, Milan, Italy. Electronic address: salonia.andrea@hsr.it.

Carlo Bettocchi (C)

Department of Urology, University of Foggia, Foggia, Italy.

Luca Boeri (L)

Department of Urology, Foundation IRCCS Ca' Granda - Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.

Paolo Capogrosso (P)

Department of Urology and Andrology, Ospedale di Circolo and Macchi Foundation, Varese, Italy.

Joana Carvalho (J)

CPUP: Center for Psychology of Porto University, Faculty of Psychology and Educational Sciences, Porto University, Porto, Portugal.

Nusret Can Cilesiz (NC)

Department of Urology, Taksim Training & Research Hospital, Istanbul, Turkey.

Andrea Cocci (A)

Department of Minimally Invasive and Robotic Urologic Surgery and Kidney Transplantation, University of Florence, Florence, Italy.

Giovanni Corona (G)

Endocrinology Unit, Medical Department, Maggiore-Bellaria Hospital, Bologna, Italy.

Kostantinos Dimitropoulos (K)

Academic Urology Unit, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK; Department of Urology, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, UK.

Murat Gül (M)

School of Medicine, Department of Urology, Selcuk University, Konya, Turkey.

Georgios Hatzichristodoulou (G)

Department of Urology, Martha-Maria Hospital Nuremberg, Nuremberg, Germany.

T Hugh Jones (TH)

Centre for Diabetes and Endocrinology, Barnsley Hospital NHS Trust, Barnsley, UK.

Ates Kadioglu (A)

Department of Urology, İstanbul University İstanbul School of Medicine, İstanbul, Turkey.

Juan Ignatio Martínez Salamanca (JI)

Department of Urology, Hospital Universitario Puerta de Hierro-Majadahonda, Lyx Institute of Urology, Universidad Francisco de Vitoria, Madrid, Spain.

Uros Milenkovic (U)

Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Vaibhav Modgil (V)

Manchester Andrology Centre, Manchester Royal Infirmary, Manchester University Hospitals NHS Foundation Trust, Manchester, UK.

Giorgio Ivan Russo (GI)

Urology Section, Department of Surgery, University of Catania, Catania, Italy.

Ege Can Serefoglu (EC)

Department of Urology, Biruni University School of Medicine, Istanbul, Turkey.

Tharu Tharakan (T)

Department of Urology, Imperial Healthcare NHS Trust, Charing Cross Hospital, London, UK; Section of Investigative Medicine, Department of Medicine, Imperial College London, London, UK.

Paolo Verze (P)

Department of Medicine and Surgery "Scuola Medica Salernitana", University of Salerno, Fisciano, Campania, Italy.

Suks Minhas (S)

Department of Urology, Imperial Healthcare NHS Trust, Charing Cross Hospital, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH